Cortagen
Cortagen is a peptide, indexed here under Short peptide bioregulators.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Short peptide bioregulators |
| CAS registry number | 335591-03-2[1] |
| PubChem CID | 18439621[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C17H26N4O9[1] |
| Molecular weight | 430.4 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Cortagen is the synthetic tetrapeptide Ala-Glu-Asp-Pro, described in a 2004 Neuroendocrinology Letters paper as a brain cortex tetrapeptide whose effect on gene expression in mouse heart was examined by microarray. Its retrieved literature is small and comes from the St Petersburg bioregulator programme.
A 2000 Bulletin of Experimental Biology and Medicine paper and a 2002 Doklady Biological Sciences paper report sciatic nerve regeneration and the delayed effect on restoration of injured nerve function in animal models, a 2011 Eksperimental’naia i Klinicheskaia Farmakologiia paper examines cortexin and cortagen in functional and metabolic disorders of the brain in chronic ischaemia, and a 2008 Advances in Gerontology paper reports effects of epithalon and cortagen on immunity and haemostasis in hypophysectomised chickens and old birds.
[3, 4, 5, 6, 7]Reported mechanism
A tetrapeptide bioregulator; the retrieved records report effects on gene expression and on nerve regeneration in animal models, with no receptor target named.
[3, 4]Stated in the titles of the cited 2004 Neuroendocrinology Letters and 2000 Bulletin of Experimental Biology and Medicine papers.
Targets named in the cited records: gene expression, peripheral nerve regeneration.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Cortagen appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- Ala-Glu-Asp-Pro
- AEDP peptide
- cortagene
Where this page sits
Research records
Cited research records for Cortagen, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
Class page: Short peptide bioregulators. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Cortagen?
Cortagen is the synthetic tetrapeptide Ala-Glu-Asp-Pro, described in a 2004 Neuroendocrinology Letters paper as a brain cortex tetrapeptide whose effect on gene expression in mouse heart was examined by microarray. Its retrieved literature is small and comes from the St Petersburg bioregulator programme.
Which class is Cortagen indexed under?
Cortagen is indexed under Short peptide bioregulators. This class groups the short synthetic peptides and tissue polypeptide extracts developed by the St Petersburg bioregulator programme, which research-peptide catalogues sell as a family.
What does the FDA application register show for Cortagen?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- PubChem Compound Summary for CID 18439621, Cortagen. PubChem, National Library of Medicine (2026). pubchem:18439621
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:cortagen
- Elucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarray. Neuro endocrinology letters (2004). pmid:15159690
- Effect of tetrapeptide cortagen on regeneration of sciatic nerve. Bulletin of experimental biology and medicine (2000). pmid:11276314
- The delayed effect of cortagen on the restoration of injured nerve function. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections (2002). pmid:12134478
- [Cortexin and cortagen as correcting agents in functional and metabolic disorders in the brain in chronic ischemia]. Eksperimental'naia i klinicheskaia farmakologiia (2011). pmid:21476278
- [Effects of epithalon and cortagene on immunity and hemostasis in neonatally hypophysectomized chicken and old birds]. Advances in gerontology = Uspekhi gerontologii (2008). pmid:19432169
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.